BMC Cancer (Jun 2023)

Interferon-induced transmembrane protein 3 in hepatocellular carcinoma patients

  • Rania M. Bondok,
  • Lamiaa A. Barakat,
  • Alyaa R. Elsergany,
  • Nancy Mahsoub,
  • Maivel H. Ghattas

DOI
https://doi.org/10.1186/s12885-023-11071-2
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Objective The study aimed to investigate the over expression of IFITM3 in hepatocellular carcinoma Egyptian patients. Background Hepatocellular carcinoma (HCC) continues to be a serious disease burden. Interferon Induced Transmembrane protein 3 (IFITM3) is a protein that encoded in humans by the IFITM3 gene. It plays a critical role in the immune system’s defense, responsible for a large portion of the antiviral activity. In this study, we showed that IFITM3 rs 12252-CC was over expressed in HCC patients compared to control group with HCV infection. Method DNA sequencing was applied for detection of IFITM3 rs 12252-CC and IFITM3 protein level was measured by ELISA to 50 patients with HCC with cirrhosis and 50 with Hepatitis C virus infection. Results The obtained results of this study indicated that IFITM3 rs 12252-CC was significantly elevated in HCC group, the codominant model of CC genotype of IFITM3 gene had high association with risk of hepatocellular carcinoma with odd ratio (OR) = 2.70, p = 0.041. Conclusion IFITM3 play an important role in progression of hepatocellular carcinoma. Results revealed that IFITM3 rs 12252-CC among Hepatocellular carcinoma patients would allow diagnosis and starting intervention.

Keywords